Adicet Bio Inc. Reports Q3 2025 Financial Results

Adicet Bio Inc ( (ACET) ) has released its Q3 earnings. Here is a breakdown of the information Adicet Bio Inc presented to its investors.

Adicet Bio Inc. is a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. In its latest earnings report for the quarter ending September 30, 2025, Adicet Bio Inc. highlighted its ongoing efforts in advancing its pipeline of ‘off-the-shelf’ gamma delta T cells, engineered with chimeric antigen receptors (CARs). The company reported a net loss of $26.9 million for the quarter, a slight improvement from the $30.5 million loss in the same period last year. Total operating expenses decreased to $28 million from $33.2 million, driven by reduced research and development costs. Despite the financial losses, the company’s cash and cash equivalents, along with short-term investments, totaled $103.1 million, which is expected to support its operations for at least the next twelve months. Looking ahead, Adicet Bio Inc. remains focused on advancing its clinical trials and securing regulatory approvals, while navigating the challenges of the biotechnology industry.